Abu Dhabi’s Technology Innovation Institute Unveils the Arab World’s First Electromagnetic Compatibility Labs
3.5.2021 11:01:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Centre (DERC) has unveiled its Electromagnetic Compatibility (EMC) laboratories in Abu Dhabi, housed in a first of its kind facility in the Arab world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005336/en/
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre, Technology Innovation Institute (Photo: AETOSWire)
The facility is composed of three laboratories - an EMC semi-anechoic chamber, a pulsed power laboratory, and a low-noise emanation laboratory.
The DERC facility enables key technologies to be evaluated against electromagnetic compatibility and interference by reproducing man-made and natural electromagnetic hazards in the pulsed power and semi-anechoic chambers. The direct connection between the two chambers enables a diversity of experiments involving 100’s of kV nanosecond pulses and multi-megawatt microwaves systems. The laboratories have been designed to host different categories of equipment such as connected objects of the Internet of Things, drones and autonomous cars, telecommunications equipment, medical devices, automotive equipment, IT equipment and is fully automated for tests and measurements. A unique low-noise emanation lab has been built on DERC specifications that allow for the study of very low noises emitted by electronic systems.
Electromagnetic compatibility, or EMC, allows electronic devices that are near each other to operate without mutual interference, known as Electromagnetic Interference, EMI. The operation of electronic circuits can be compromised as they can radiate or pick up unwanted interference. Highlighting the significance of EMC is the fact that the number of devices connected wirelessly is constantly on the rise.
H.E. Faisal Al Bannai, Secretary General of ATRC, said: “The launch of these labs, which are the first and the largest in the Arab world, is aligned with the Ministry of Industry and Advanced Technology’s (MoIAT) ’Operation 300bn’ which aims to advance the industrial sector, a mandate which we fully support at ATRC as the organisation defining Abu Dhabi’s and the UAE’s research strategy across academia and industry. ATRC is investing in cutting-edge laboratories that will support in-country R&D and local industry, and encourage innovation in line with international standards. By opening these unique laboratories, non-existent before in the Arab region, we want to support innovators from prototype to a qualified system.”
DERC is pioneering research in high energy physics, and the effects of high intensity fields on different materials, systems, and environments. The Centre is committed to using its cutting-edge position in science to search for practical solutions that benefit society in diverse areas. In EMC/EMI, DERC’s research domains include modelling of the EM environment produced by human-made sources; design, production, and evaluation of antennas; innovative materials for EM shielding applications; modelling of the electro-thermal response of industrial systems; and lightning protection.
Dr. Chaouki Kasmi, Chief Researcher at Directed Energy Research Centre, said: “At DERC we support research on a wide range of topics in EMC and EMI on behalf of governments and enterprises to help create and maintain advanced electronic systems. We are excited to announce the launch of the EMC labs in Abu Dhabi. They will help in pre-qualification of electronics against Electromagnetic Compatibility and Interference Standards as well as hardening of critical infrastructures to operate safely in harsh environments.”
“Many electromagnetic compatibility standards have been introduced over the years, making EMC a key part of the electronics design process,” Dr. Kasmi said. “With standards now implemented and enforced globally, manufacturers have to ensure that new electronic products meet the relevant EMC standards.”
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005336/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom